Lpl Financial LLC Corbus Pharmaceuticals Holdings, Inc. Transaction History

Lpl Financial LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.17 - $5.31 $4,080 - $127,439	24,000 Added 18.54%	153,478 $25,000
Q2 2022 Aug 12, 2022	BUY	$0.21 - $0.53 $136 - $345	651 Added 0.51%	129,478 $33,000
Q1 2022 May 16, 2022	SELL	$0.32 - $0.67 $843 - $1,765	-2,635 Reduced 2.0%	128,827 $68,000
Q4 2021 Feb 14, 2022	BUY	$0.6 - $1.11 $4,230 - $7,825	7,050 Added 5.67%	131,462 $81,000
Q3 2021 Nov 15, 2021	BUY	$1.01 - $1.82 $47,882 - $86,282	47,408 Added 61.57%	124,412 $127,000
Q2 2021 Aug 13, 2021	BUY	$1.39 - $2.21 $3,775 - $6,002	2,716 Added 3.66%	77,004 $141,000
Q1 2021 May 14, 2021	BUY	$1.27 - $3.42 $48,848 - $131,543	38,463 Added 107.36%	74,288 $146,000
Q4 2020 Feb 12, 2021	BUY	$0.94 - $1.89 $20,915 - $42,052	22,250 Added 163.9%	35,825 $45,000
Q3 2020 Nov 09, 2020	BUY	$1.5 - $9.38 $3,637 - $22,746	2,425 Added 21.75%	13,575 $24,000
Q2 2020 Aug 13, 2020	BUY	$4.79 - $8.39 $53,408 - $93,548	11,150 New	11,150 $94,000
Q2 2019 Aug 09, 2019	SELL	$6.6 - $7.8 $93,970 - $111,056	-14,238 Closed	0 $0
Q1 2019 May 08, 2019	BUY	$5.76 - $8.95 $82,010 - $127,430	14,238 New	14,238 $99,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $1.22B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Lpl Financial LLC with notifications on news.